Targeting a blood stem cell subset shows lasting, therapeutically relevant gene editing

Researchers have used CRISPR-Cas9 to edit long-lived blood stem cells to reverse the clinical symptoms observed with several blood disorders, including sickle cell disease and beta-thalassemia.